Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 23 of 23 publications.

Fliser D, Portoles J, Houghton K, Ainsworth C, Blogg M, Lorenzo MM. Treatment structures and resource use in non-dialysis-dependent CKD patients (NDD-CKD) with renal anemia: a retrospective analysis. Poster presented at the Kongress fur NepHROlogie 2021 13th Annual Meeting; September 23, 2021.

Fliser D, Portoles J, Houghton K, Ainsworth C, Blogg M, Lorenzo MM. Treatment of anaemia with erythropoiesis-stimulating agents (ESAs) and concomitant therapies among patients with non-dialysis dependent chronic kidney disease (NDD-CKD) in Germany, Spain and the UK: a retrospective chart review. Poster presented at the 2021 58th ERA-EDTA Virtual Congress; June 5, 2021.

Mader G, Mladsi (she/her) D, Zhou X, Sanon M, Wang J, Willey C, Seliger S. Racial differences in mortality rates among elderly Non-ESRD CKD and ESRD patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD): study findings using data from the USRDS. Poster presented at the Virtual National Kidney Foundation 2021 Spring Clinical Meetings; April 2021.

Mader G, Purser M, Mladsi D, Sanon M, Oberdhan D, Watnick T, Seliger S. Benefit of tolvaptan on time to End-stage Renal Disease (ESRD) for patients with rapidly progressing Autosomal Dominant Polycystic Kidney Disease (ADPKD): a disease progression model. Poster presented at the 2020 National Kidney Foundation Spring Clinical Meeting; March 2020. New Orleans, LA. [abstract] Am J Kidney Dis. 2020 Apr; 75(4):603.

Ridenour TA, Stull D. Potential utility of idiographic clinical trials in drug development. Value & Outcomes Spotlight. 2018 Mar;4(2):25-9.

DaCosta Byfield S, McPheeters JT, Burton T, Nagar SP, Hackshaw MD. Persistence and compliance among US patients receiving pazopanib or sunitinib as first-line therapy for advanced renal cell carcinoma. J Manag Care Pharm. 2015 Jun;21(6):515-22.

Hansen RN, Hackshaw MD, Nagar SP, Arondekar B, Deen KC, Sullivan SD, Ramsey SD. Health care costs among renal cancer patients using pazopanib and sunitinib. J Manag Care Pharm. 2015 Jan;21(1):37-44.

Davis AE, Mehrotra S, Kilambi V, Kang J, McElroy L, Lapin B, Holl J, Abecassis M, Friedewald JJ, Ladner DP. The effects of the statewide sharing variance on geographic disparity in kidney transplantation in the United States. Clin J Am Soc Nephrol. 2014 Aug 7;9(8):1149-60.

Hackshaw MD, Nagar SP, Parks DC, Miller LA. Persistence and compliance with Pazopanib in patients with advanced renal cell carcinoma within a U.S. administrative claims database. J Manag Care Pharm. 2014 Jun;20(6):603-10.

Ferguson JE3rd, Goyal RK, Raynor MC, Nielsen ME, Pruthi RS, Brown PM, Wallen EM. Cost analysis of robot-assisted laparoscopic versus hand-assisted laparoscopic partial nephrectomy. J Endourol. 2012 Aug;26(8):1030-7.

Lang K, Meyers JL, Kovacs B, Candrilli SD. Renal impairment in patients with type 2 diabetes mellitus and associated antihyperglycemic medication adjustment: evidence from an electronic medical records database. Poster presented at the 43rd Annual Meeting and Scientific Exposition of the American Society of Nephrology; November 2010.

Davis AE, Ladner D, Friedewald J. Analysis of dialysis center locations in Illinois. Poster presented at the American Transplant Congress; May 2010.

Shirley DG, Vekaria RM, Sevigny J. Ectonucleotidases in the kidney. Purinergic Signal. 2009 Dec;5(4):501-11. doi: 10.1007/s11302-009-9152-4

Bapat BS, Mitra D, Keith M. Phosphate binder utilization patterns for the treatment of hyperphosphatemia in chronic kidney disease patients.. Poster presented at the Academy of Managed Care Pharmacy 2009 Educational Conference; October 2009.

Bapat BS, Keith M, Mitra D. Augmentation and switch patterns associated with hyperphosphatemia treatment in chronic kidney disease patients.. Poster presented at the Academy of Managed Care Pharmacy 2009 Educational Conference; October 2009.

Keith M, Mitra D, Bapat BS. Comparing drug utilization and phosphate reduction among phosphate binder treatments used in chronic kidney disease patients.. Poster presented at the American Society of Nephrology 42nd Annual Meeting & Scientific Exposition; October 2009.

Stull DE, Depueto J, Galain AI. Some determinants of HRQL in patients with ESRD: the case of Uruguay. Presented at the 15th Annual Conference of the International Society for Quality of Life Research; October 2008.

Pearson IV, Johnson KI. A cost minimization analysis of epoetin zeta for the treatment of anemia associated with chronic kidney disease. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 2008. [abstract] Value Health. 2008 May; 11(3):A304.

Subramanian S, Bapat BS, Tumlin J, Zyczynski T. Economic burden of contrast-induced nephropathy (CIN): implications for guideline development. Poster presented at the Transcatheter Cardiovascular Therapeutics; October 2007.

Subramanian S, Bapat BS, Tumlin J, Zyczynski T. Economic burden of contrast-induced nephropathy (CIN): implications for prevention strategies. Poster presented at the 7th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke; May 2007. Previously presented at the International Society for Pharmacoeconomics and Outcomes Research 9th Annual European Congress.

Subramanian S, Tumlin J, Bapat B, Zyczynski T. Economic burden of contrast-induced nephropathy: implications for prevention strategies. J Med Econ. 2007 Jan 1;10(2):119-34.

Subramanian S, Bapat BS, Tumlin J, Zyczynski T. Economic burden of contrast-induced nephropathy (CIN): implications for prevention strategies. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research 9th Annual European Congress; October 2006.

Bell T, Candrilli S, Irish W, Morris E, Cairo MS. Medical resource use and costs associated with renal complications among patients with hematologic malignancies. Blood. 2002 Jan 1;100(11):221A.